What's Going On With Diebold Nixdorf Shares Today

Loading...
Loading...
  • Diebold Nixdorf Inc DBD reported a first-quarter FY21 sales decline of 12.1% year-on-year to $829.8 million, missing the consensus of $925.12 million.
  • Revenue from Eurasia Banking decreased 15.2% to $277.9 million, Americas Banking fell 8.6% to $284.8 million, and Retail declined 12.3% to $267.1 million.
  • The gross profit declined 32.2% Y/Y to $185.3 million, with the margin shrinking 660 basis points to 22.3%.
  • Adjusted operating loss for the quarter was $(7.3) million.
  • The company held $266.8 million in cash and equivalents as of March 31, 2022.
  • Adjusted EBITDA fell 90.6% Y/Y to $9.4 million.
  • Adjusted EPS loss of $(1.61) missed the analyst consensus of $(0.20).
  • "We expect to see significant cost savings of more than $150 million over the next 12 to 18 months and a return to our original financial growth, profitability, and free cash flow targets by 2024," said CEO Octavio Marquez.
  • Outlook: Diebold Nixdorf has cut FY22 sales guidance to $3.7 billion - $3.9 billion from $4.0 billion - $4.2 billion, versus the consensus of $4.04 billion.
  • The company expects FY22 adjusted EBITDA of $320 million - $350 million (prior view $440 million - $460 million).
  • Price Action: DBD shares are trading lower by 30.4% at $2.66 on the last check Tuesday.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksGuidanceMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...